Leo Cancer Care

Leo Cancer CareLeo Cancer Care
Leo Cancer Care

Leo Cancer Care

Reinventing cancer imaging and treatment through upright patient positioning.

DR 44Speed 532019Active123Middleton, USA
Rate

About

Leo Cancer Care is a medical technology company focused on developing innovative systems for cancer imaging and treatment. Their core innovation lies in designing systems that accommodate the body's natural upright position, aiming to improve patient comfort and potentially enhance treatment efficacy. The company recently closed an oversubscribed $65 million Series D financing round.
Frequently asked

What does Leo Cancer Care do?

Leo Cancer Care is a medical technology company focused on developing innovative systems for cancer imaging and treatment. Their core innovation lies in designing systems that accommodate the body's natural upright position, aiming to improve patient comfort and potentially enhance treatment efficacy. The company recently closed an oversubscribed $65 million Series D financing round.

What is Leo Cancer Care's revenue?

StartupHub estimates Leo Cancer Care's annual revenue at $24.6M (range $13.4M to $58.2M, 64% confidence), based on comparable companies in the sector.

What is Leo Cancer Care's valuation?

StartupHub estimates Leo Cancer Care's effective valuation at $258.6M (range $162.5M to $390.0M, 23% confidence), based on comparable companies in the sector.

How much funding has Leo Cancer Care raised?

Leo Cancer Care has raised a total of $65M in funding. The most recent round on record is Series D.

Where is Leo Cancer Care headquartered?

Leo Cancer Care is headquartered in Middleton, Wisconsin, USA.

When was Leo Cancer Care founded?

Leo Cancer Care was founded in 2019.

What industry does Leo Cancer Care operate in?

Leo Cancer Care operates in HealthTech, Medical Devices, Oncology, MedTech, Cancer Treatment, Medical Imaging.

How many employees does Leo Cancer Care have?

Leo Cancer Care has approximately 123 people on record.

HEADCOUNT
123
DOMAIN RATING
44
Comments

No comments yet. Be the first to share your take.